Other substances

AOaV-1-SARS-CoV-2

COVID-19 candidate vaccine

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

AOaV-1-SARS-CoV-2 is a de novo synthesized avian orthoavulavirus 1 (AOaV-1)-based topical respiratory vaccine candidate against COVID-19. An avirulent strain of Newcastle disease virus, proto-type virus of AOaV-1, was engineered to express full-length spike (S) glycoprotein which is a highly neutralizing and major protective antigen of the SARS-CoV-2.

 

Supporting references

Link Tested on Impact factor Notes Publication date
A Scalable Topical Vectored Vaccine Candidate Against SARS-CoV-2
VERO cells and embryonated chicken eggs 4.09 Aug/24/2020
Export (.csv)